I don’t think there’s anyone who likes popping pills for an ailment. Internal chemistry is a delicate cocktail, after all.
Well, a partnership between two tech and healthcare juggernauts may soon do their part to end the “better living through chemistry” motto and skip the pills by moving from chemistry to technology.
Google’s parent company Alphabet (Nasdaq: GOOGL) has partnered with leading British pharmaceutical firm GlaxoSmithKline (NYSE: GSK) to launch a new “bioelectronics medicine” company.
Bioelectric medicine is a new field of research focusing on tiny implanted devices that alter a person’s electrical nerve signal to treat chronic conditions like arthritis, diabetes, and asthma.
Economist Harry S. Dent Jr. now has indisputable evidence of precisely where gold is heading next.
A Pretty Big Bet
Laying their reputations on the line, both companies forecast this new technology will foster the next medical revolution. Called Galvani Bioelectronics, the joint venture will receive $715 million in funding over the next seven years.
Like all good risk-averse companies, GlaxoSmithKline (GSK) isn’t putting all their “tech eggs” in one basket solely with Alphabet. GSK announced the day before that they are also partnering with Apple (Nasdaq: AAPL) to leverage their medical research capability, called ResearchKit.
Apple, along with other traditional tech companies, are starting to diversify their portfolios into the healthcare industry. They’re focusing their deep knowledge of massive IT infrastructures, as well as computing, and applying this expertise to challenging medical issues.
As the healthcare industry goes digital, more medical breakthroughs occur through plain old computer data crunching.
Bigger Than an iPhone
With the data for a single human genome measuring roughly 100 gigabytes in size (average storage capacity for the top tier iPhone), medical companies simply require the data processing power associated with large IT companies.
By applying genome data with highly targeted treatment options and stats culled from a patient’s medical history, plus regional health/lifestyle data and a fitness tracker, providers hope to build a better and more complete health picture.
Physicians have an uphill battle leveraging this data fully with their current tools. Alphabet, Apple, and even Microsoft hope to change that by offering their infrastructure to crunch these massive data sets for precision medicine.
Data points to make our medicine options more precise are growing at an exponential rate.
Enough to Make Your Skin Tingle
Engineers at Tufts University have been integrating microfluidics, electronics, and nanoscale sensors into suture threads.
These threads contain high-end electronics designed to suture down through multiple layers of skin and tissue.
Once sutured, the threads would provide wireless information on underlying tissue, in real time, to alert doctors of possible infections or relevant healing data.
Results in the Journal of Microsystems & Nanoengineering look genuinely promising for use in a variety of specific cases.
Bottom line: this technology would add one more calculated data point to everything else we currently utilize to provide a whole health picture.
Bioelectronic treatments, smart sutures, and massive health data crunching will no doubt disrupt the current health and IT industries in the coming years.
Count on your Dent Research team to provide you the latest insights into technology that you can profit from for market plays.
Editor, BioTech Intel Trader